{"id":352231,"date":"2025-08-26T07:26:00","date_gmt":"2025-08-26T07:26:00","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-diagnostics\/"},"modified":"2025-08-26T07:26:00","modified_gmt":"2025-08-26T07:26:00","slug":"how-to-buy-diagnostics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/","title":{"rendered":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-352231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Co-Diagnostics (CODX) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 ticaret f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Co-Diagnostics (CODX) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 ticaret f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin."},"intro":"Biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n heyecan verici d\u00fcnyas\u0131na dalmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Co-Diagnostics (CODX), portf\u00f6y\u00fcn\u00fcz\u00fc d\u00f6n\u00fc\u015ft\u00fcrebilecek veya piyasa volatilitesi hakk\u0131nda de\u011ferli dersler \u00f6\u011fretebilecek y\u00fcksek riskli, y\u00fcksek getirili f\u0131rsatlar\u0131n tam da \u00f6rne\u011fini temsil ediyor. Bu molek\u00fcler tan\u0131 \u015firketi, PCR test teknolojisinde s\u0131n\u0131rlar\u0131 zorlarken, kuru\u015f hisse senedi seviyelerinde i\u015flem g\u00f6r\u00fcyor - bu da eri\u015filebilir k\u0131l\u0131yor ancak dikkatli bir strateji gerektiriyor. Bu yenilik\u00e7i sa\u011fl\u0131k oyununu yat\u0131r\u0131m listenize eklemeye de\u011fer mi, birlikte ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n heyecan verici d\u00fcnyas\u0131na dalmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Co-Diagnostics (CODX), portf\u00f6y\u00fcn\u00fcz\u00fc d\u00f6n\u00fc\u015ft\u00fcrebilecek veya piyasa volatilitesi hakk\u0131nda de\u011ferli dersler \u00f6\u011fretebilecek y\u00fcksek riskli, y\u00fcksek getirili f\u0131rsatlar\u0131n tam da \u00f6rne\u011fini temsil ediyor. Bu molek\u00fcler tan\u0131 \u015firketi, PCR test teknolojisinde s\u0131n\u0131rlar\u0131 zorlarken, kuru\u015f hisse senedi seviyelerinde i\u015flem g\u00f6r\u00fcyor - bu da eri\u015filebilir k\u0131l\u0131yor ancak dikkatli bir strateji gerektiriyor. Bu yenilik\u00e7i sa\u011fl\u0131k oyununu yat\u0131r\u0131m listenize eklemeye de\u011fer mi, birlikte ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2> <p>26 A\u011fustos 2025 itibar\u0131yla, Co-Diagnostics, Inc. (CODX) hisseleri <strong>0,32 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor ve bu, ileri teknoloji molek\u00fcler tan\u0131 alan\u0131na maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in inan\u0131lmaz bir f\u0131rsat sunuyor. Bu fiyat seviyesi CODX'i kesinlikle kuru\u015f hisse senedi kategorisine yerle\u015ftiriyor, ancak bu sizi yan\u0131ltmas\u0131n - \u015firketin teknolojisi uygun fiyatl\u0131 PCR testlerini d\u00fcnya \u00e7ap\u0131nda devrim niteli\u011finde de\u011fi\u015ftirebilir.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: \u015eirketin bir sonraki kazan\u00e7 raporunu yay\u0131nlamas\u0131 beklenen <strong>Kas\u0131m 2025<\/strong> tarihini takviminize i\u015faretleyin. Tarihsel olarak, biyoteknoloji kazan\u00e7lar\u0131, duyurudan sonraki g\u00fcnlerde fiyatlarda %20-50 aras\u0131nda b\u00fcy\u00fck dalgalanmalara neden olabilir.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>Son performans desenlerine bakmak, Co-Diagnostics, Inc. (CODX) hissesine yat\u0131r\u0131m zamanlamas\u0131 i\u00e7in kritik i\u00e7g\u00f6r\u00fcler sa\u011flar:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><th>S\u00fcre<\/th><\/tr> <\/thead> <tbody> <tr><td>14 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>0,27 $<\/td><td>%18,5 Art\u0131\u015f (1 hafta)<\/td><td>S\u00fcrd\u00fcr\u00fclebilir<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>T\u00fcm Zamanlar\u0131n En D\u00fc\u015f\u00fc\u011f\u00fc<\/td><td>0,23 $<\/td><td>%39 Kurtarma<\/td><td>3 ay<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>D\u00fcnya Kanser G\u00fcn\u00fc<\/td><td>0,45 $<\/td><td>%12 Momentum<\/td><td>2 hafta<\/td><\/tr> <tr><td>Kas 2024<\/td><td>Platform Lansman\u0131<\/td><td>0,82 $<\/td><td>%28 D\u00fczeltme<\/td><td>1 ay<\/td><\/tr> <tr><td>A\u011fu 2024<\/td><td>2. \u00c7eyrek 2024<\/td><td>1,15 $<\/td><td>%45 D\u00fc\u015f\u00fc\u015f<\/td><td>6 ay<\/td><\/tr> <\/tbody> <\/table> <p>Desen, olumlu klinik deneme g\u00fcncellemeleri veya d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131n\u0131n genellikle en s\u00fcrd\u00fcr\u00fclebilir kazan\u00e7lar\u0131 tetikledi\u011fini, kazan\u00e7 ka\u00e7\u0131rmalar\u0131n\u0131n ise keskin ancak genellikle ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden oldu\u011funu g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2> <p>Co-Diagnostics, 2025 y\u0131l\u0131n\u0131n ilk sekiz ay\u0131nda tam bir h\u0131z treni ya\u015fad\u0131 ve biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n neden g\u00fc\u00e7l\u00fc sinirler ve stratejik zamanlama gerektirdi\u011fini tam olarak g\u00f6sterdi:<\/p> <p><strong>Ocak-Mart 2025<\/strong>: \u015eirket, Logix Smart platformu i\u00e7in b\u00fcy\u00fck sa\u011fl\u0131k fuarlar\u0131na kat\u0131l\u0131rken hisse senedi 0,45-0,60 $ aras\u0131nda i\u015flem g\u00f6rd\u00fc ve piyasa fark\u0131ndal\u0131\u011f\u0131 olu\u015fturdu.<\/p> <p><strong>Nisan-May\u0131s 2025<\/strong>: Nakit yakma oranlar\u0131 ve gecikmi\u015f d\u00fczenleyici zaman \u00e7izelgeleri endi\u015feleri nedeniyle 22 May\u0131s'ta <strong>t\u00fcm zamanlar\u0131n en d\u00fc\u015f\u00fck seviyesi olan 0,2275 $<\/strong> seviyesine sert bir d\u00fc\u015f\u00fc\u015f ya\u015fand\u0131.<\/p> <p><strong>Haziran-A\u011fustos 2025<\/strong>: Beklenenden iyi gelen 2. \u00e7eyrek kazan\u00e7lar ve Co-Dx PCR platform geli\u015ftirmesindeki devam eden ilerlemeyle desteklenen <strong>%39'luk dikkate de\u011fer bir toparlanma<\/strong> ya\u015fand\u0131 ve fiyatlar yakla\u015f\u0131k 0,32 $ seviyesine y\u00fckseldi.<\/p> <p>Genel alt\u0131 ayl\u0131k performans, erken a\u015fama biyoteknoloji \u015firketlerine \u00f6zg\u00fc a\u015f\u0131r\u0131 volatilite ile <strong>V \u015feklinde bir toparlanma modeli<\/strong> g\u00f6steriyor. Hissenin beta katsay\u0131s\u0131 1,44 olup, piyasan\u0131n genelinden \u00e7ok daha fazla hareket etti\u011fini do\u011fruluyor ve sadece risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Co-Diagnostics'in \u00fcr\u00fcn hatt\u0131 ilerlemesi, piyasa konumu ve sekt\u00f6r trendlerinin kapsaml\u0131 analizine dayanarak, yat\u0131r\u0131mc\u0131lar\u0131n bekleyebilece\u011fi \u015funlard\u0131r:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: <strong>0,45-0,65 $<\/strong> - Platform geli\u015ftirmesinin devam\u0131 ve potansiyel d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 mevcut seviyelerden %40-100 aras\u0131 y\u00fckseli\u015f sa\u011flayabilir. \u2192 <strong>R\u0130SK TOLERANSI Y\u00dcKSEK YATIRIMCILAR \u0130\u00c7\u0130N SPEK\u00dcLAT\u0130F ALIM<\/strong><\/li> <li><strong>2026 Tahmini<\/strong>: <strong>0,80-1,20 $<\/strong> - Ba\u015far\u0131l\u0131 FDA ba\u015fvurular\u0131 ve ilk ticari lansmanlar i\u015f modelini do\u011frulayabilir ve kurumsal ilgiyi \u00e7ekebilir.<\/li> <li><strong>2028 Projeksiyonu<\/strong>: <strong>2,50-4,00 $<\/strong> - Birden fazla test paneli ve co\u011frafi pazarda tam ticarile\u015fme s\u00fcrd\u00fcr\u00fclebilir gelir ak\u0131\u015flar\u0131 olu\u015fturabilir.<\/li> <li><strong>2030 Vizyonu<\/strong>: <strong>5,00-8,00 $<\/strong> - Uygun fiyatl\u0131 PCR testlerinde pazar liderli\u011fi ve daha b\u00fcy\u00fck tan\u0131 \u015firketlerinden potansiyel sat\u0131n alma ilgisi.<\/li> <\/ul> <p><em>Karar<\/em>: CODX, y\u00fcr\u00fctme ba\u015far\u0131l\u0131 olursa 5 y\u0131l i\u00e7inde 15-25 kat getiri sa\u011flayabilecek y\u00fcksek riskli, potansiyel olarak y\u00fcksek getirili bir yat\u0131r\u0131md\u0131r, ancak d\u00fczenleyici veya finansman zorluklar\u0131 ortaya \u00e7\u0131karsa \u00f6nemli d\u00fc\u015f\u00fc\u015fler de ya\u015fayabilir.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <p>Co-Diagnostics, Inc. (CODX) hissesine yat\u0131r\u0131m yaparken bu kritik riskleri anlamak gerekir:<\/p> <h3>Y\u00fcksek Etkili Riskler<\/h3> <ul> <li><strong>D\u00fczenleyici Onay Gecikmeleri<\/strong>: \u015eirketin t\u00fcm de\u011feri, test panelleri i\u00e7in ba\u015far\u0131l\u0131 FDA 510(k) ba\u015fvurular\u0131na ba\u011fl\u0131d\u0131r. Herhangi bir gecikme veya reddedilme, hisse fiyat\u0131n\u0131 g\u00fcnler i\u00e7inde %50-70 oran\u0131nda d\u00fc\u015f\u00fcrebilir.<\/li> <li><strong>Nakit Yakma Krizi<\/strong>: 13,4 milyon $ rezerv ve \u00e7eyreklik yakla\u015f\u0131k 7,7 milyon $ zarar ile \u015firketin ek finansman gerektirmeden \u00f6nce yakla\u015f\u0131k 4-5 \u00e7eyreklik nakit \u00f6mr\u00fc vard\u0131r; bu finansman mevcut hissedarlar\u0131n hisselerini seyreltebilir.<\/li> <li><strong>M\u00fc\u015fteri Yo\u011funla\u015fmas\u0131<\/strong>: \u00dcr\u00fcn gelirinin %53'\u00fc \u00fc\u00e7 m\u00fc\u015fteriden gelmekte olup, herhangi bir b\u00fcy\u00fck m\u00fc\u015fterinin sipari\u015fleri azaltmas\u0131 veya tedarik\u00e7iyi de\u011fi\u015ftirmesi durumunda k\u0131r\u0131lganl\u0131k yaratmaktad\u0131r.<\/li> <\/ul> <h3>Piyasa Riskleri<\/h3> <ul> <li><strong>Biyoteknoloji Sekt\u00f6r\u00fc Volatilitesi<\/strong>: 2025'te sekt\u00f6r genel olarak yat\u0131r\u0131mc\u0131lar taraf\u0131ndan tercih edilmemekte, bu da sermaye eri\u015fimini azaltmakta ve geli\u015fim a\u015famas\u0131ndaki \u015firketler i\u00e7in bor\u00e7lanma maliyetlerini art\u0131rmaktad\u0131r.<\/li> <li><strong>Rekabetin Yo\u011funla\u015fmas\u0131<\/strong>: Daha b\u00fcy\u00fck ve daha derin ceplere sahip tan\u0131 \u015firketleri, Co-Diagnostics'in pazar avantaj\u0131n\u0131 zay\u0131flatabilecek uygun fiyatl\u0131 PCR platformlar\u0131 geli\u015ftirebilir.<\/li> <\/ul> <h2>\ud83d\udfe2 Olumlu Sinyaller: Neden \u015eimdi Almay\u0131 D\u00fc\u015f\u00fcnmelisiniz?<\/h2> <p>Risklere ra\u011fmen, Co-Diagnostics, Inc. (CODX) hissesine yat\u0131r\u0131m yapmay\u0131 destekleyen birka\u00e7 g\u00fc\u00e7l\u00fc fakt\u00f6r vard\u0131r:<\/p> <ul> <li><strong>Teknoloji Farkl\u0131la\u015fmas\u0131<\/strong>: Patentli Co-Primers teknolojisi, PCR do\u011frulu\u011fu ve maliyet azalt\u0131m\u0131nda ger\u00e7ek bilimsel avantaj sa\u011flar ve hakemli ara\u015ft\u0131rmalarla do\u011frulanm\u0131\u015ft\u0131r.<\/li> <li><strong>Piyasa Zamanlamas\u0131<\/strong>: Uygun fiyatl\u0131 tan\u0131 testlerine k\u00fcresel talep artmaya devam ediyor, \u00f6zellikle Co-Diagnostics'in Hindistan ve Afrika'daki ortakl\u0131klar\u0131yla odakland\u0131\u011f\u0131 geli\u015fmekte olan pazarlarda.<\/li> <li><strong>Son Momentum<\/strong>: May\u0131s ay\u0131ndaki dipten %39'luk toparlanma, y\u00f6netimin y\u00fcr\u00fctme yeteneklerine ve zaman \u00e7izelgesine uyumuna y\u00f6nelik artan yat\u0131r\u0131mc\u0131 g\u00fcvenini g\u00f6steriyor.<\/li> <li><strong>Analist Deste\u011fi<\/strong>: Zorluklara ra\u011fmen analistler \"Al\" notlar\u0131n\u0131 koruyor ve ortalama fiyat hedefleri 5,50 $ ile %1600'den fazla potansiyel y\u00fckseli\u015fi temsil ediyor.<\/li> <li><strong>Sekt\u00f6r Etkinliklerine Kat\u0131l\u0131m<\/strong>: WHX Kuala Lumpur ve Next Generation Dx Summit'teki aktif kat\u0131l\u0131m, piyasa geli\u015ftirme ve ortakl\u0131k kurma taahh\u00fcd\u00fcn\u00fc g\u00f6steriyor.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan T\u00fcccarlar \u0130\u00e7in Stratejik Tavsiyeler<\/h2> <p>Co-Diagnostics, Inc. (CODX) hissesinin kapsaml\u0131 analizine dayanarak, bug\u00fcn hangi ad\u0131mlar\u0131n mant\u0131kl\u0131 oldu\u011fu a\u015fa\u011f\u0131da belirtilmi\u015ftir:<\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n Ama Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2'sinden fazlas\u0131n\u0131 CODX'e ay\u0131rmay\u0131n - ba\u015far\u0131l\u0131 olursa \u00f6nemli, ba\u015far\u0131s\u0131z olursa y\u0131k\u0131c\u0131 olmayacak kadar k\u00fc\u00e7\u00fck.<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede almak yerine, volatiliteyi dengelemek i\u00e7in her ay 100-200 $ de\u011ferinde hisse almay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li> <li><strong>A\u00e7\u0131k \u00c7\u0131k\u0131\u015f Kurallar\u0131 Belirleyin<\/strong>: Kar alaca\u011f\u0131n\u0131z (\u00f6rne\u011fin %100 kazan\u00e7) veya zarar kesme (\u00f6rne\u011fin %50 d\u00fc\u015f\u00fc\u015f) fiyatlar\u0131n\u0131 \u00f6nceden belirleyin, b\u00f6ylece duygusal kararlar almazs\u0131n\u0131z.<\/li> <li><strong>D\u00fczenleyici Tetikleyicileri \u0130zleyin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve FDA ba\u015fvuru duyurular\u0131 kritik olacak - bu olaylar i\u00e7in fiyat uyar\u0131lar\u0131 ayarlamay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li> <\/ol> <p><em>Esprili Deneyimli Yorum<\/em>: \"CODX ticareti, kontroller olmadan PCR yapmak gibidir - bazen harika sonu\u00e7lar al\u0131rs\u0131n\u0131z, bazen kontaminasyon olur. Her zaman duygusal koruyucu ekipman tak\u0131n!\"<\/p> <h2>\u2705 Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <p>Bu ilgin\u00e7 biyoteknoloji oyununu portf\u00f6y\u00fcn\u00fcze eklemeye haz\u0131r m\u0131s\u0131n\u0131z? \u0130\u015fte pratik yol haritan\u0131z:<\/p> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Platformunuzu Se\u00e7in<\/td><td>Makul komisyonlarla NASDAQ kuru\u015f hisse senedi ticareti sunan bir arac\u0131 kurum se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Y\u00fcksek riskli bu yat\u0131r\u0131m i\u00e7in k\u00fc\u00e7\u00fck bir miktar (100-500 $) ile ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"CODX\" Aramas\u0131 Yap\u0131n<\/td><td>Do\u011fru menkul k\u0131ymeti bulmak i\u00e7in tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Hisse miktar\u0131 ve toplam maliyet dahil olmak \u00fczere emir detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td><td>B\u00fcy\u00fck fiyat hareketleri veya haber olaylar\u0131 i\u00e7in bildirimleri yap\u0131land\u0131r\u0131n<\/td><\/tr> <tr><td>7<\/td><td>Tezinizi Belgeleyin<\/td><td>Neden yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131z\u0131 ve ne zaman sataca\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td><\/tr> <tr><td>8<\/td><td>\u00c7eyreklik \u0130zleyin<\/td><td>Kazan\u00e7 raporlar\u0131 ve klinik deneme g\u00fcncellemelerini d\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td><\/tr> <tr><td>9<\/td><td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td><td>Bekleme s\u00fcresinin sermaye kazanc\u0131 muamelesini nas\u0131l etkiledi\u011fini anlay\u0131n<\/td><\/tr> <tr><td>10<\/td><td>Bilgili Kal\u0131n<\/td><td>\u015eirket bas\u0131n b\u00fcltenlerini ve sekt\u00f6r geli\u015fmelerini takip edin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option'\u0131n CODX Yat\u0131r\u0131mc\u0131lar\u0131na \u00c7ekicili\u011fi<\/h2> <p>Co-Diagnostics gibi \u015firketlerle ilgilenen t\u00fcccarlar i\u00e7in Pocket Option, biyoteknoloji yat\u0131r\u0131m stratejileriyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, CODX yat\u0131r\u0131m tezini minimal sermaye riskiyle test edebilir ve biyoteknoloji ticaretinin inceliklerini \u00f6\u011frenebilirsiniz.<\/li> <li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci sayesinde, hesap onay\u0131 i\u00e7in g\u00fcnler beklemeden ani fiyat hareketlerinden veya son dakika haberlerinden yararlanabilirsiniz.<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100'den fazla para \u00e7ekme y\u00f6ntemi, CODX'in ba\u015far\u0131l\u0131 biyoteknoloji hisselerine \u00f6zg\u00fc patlay\u0131c\u0131 yukar\u0131 hareketlerinde karlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim sa\u011flar.<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, CODX gibi volatil hisseleri ger\u00e7ek zamanl\u0131 grafikler ve haber entegrasyonu ile izlemeyi kolayla\u015ft\u0131r\u0131r ve kritik FDA duyuru pencerelerinde bilin\u00e7li kararlar vermenize yard\u0131mc\u0131 olur.<\/p> <h2>\ud83c\udf0d 2025'te Co-Diagnostics: Tan\u0131 Devrimine Haz\u0131rl\u0131k<\/h2> <p>Co-Diagnostics, t\u0131bbi teknoloji ile k\u00fcresel sa\u011fl\u0131k eri\u015filebilirli\u011finin b\u00fcy\u00fcleyici kesi\u015fim noktas\u0131nda faaliyet g\u00f6stermektedir. \u015eirketin temel misyonu, yenilik\u00e7i Co-Dx platformu arac\u0131l\u0131\u011f\u0131yla alt\u0131n standart PCR testlerini demokratikle\u015ftirmek ve laboratuvar kalitesinde tan\u0131 hizmetlerini \u00f6nemli \u00f6l\u00e7\u00fcde azalt\u0131lm\u0131\u015f maliyetlerle sunmakt\u0131r.<\/p> <p>\u015eu anda gelir \u00f6ncesi bir yenilik\u00e7i olarak konumlanan Co-Diagnostics, COVID-19, t\u00fcberk\u00fcloz, solunum \u00e7oklu test ve HPV \u00e7oklu test olmak \u00fczere d\u00f6rt geli\u015fmi\u015f test paneli geli\u015ftirmektedir. \u015eirketin WHX Kuala Lumpur ve Next Generation Dx Summit gibi b\u00fcy\u00fck sekt\u00f6r etkinliklerine kat\u0131l\u0131m\u0131, ortakl\u0131klar kurma ve piyasa fark\u0131ndal\u0131\u011f\u0131 olu\u015fturma taahh\u00fcd\u00fcn\u00fc g\u00f6stermektedir.<\/p> <p>Ortak giri\u015fimi CoSara Diagnostics arac\u0131l\u0131\u011f\u0131yla \u015firket, \u00f6zellikle uygun fiyatl\u0131 test \u00e7\u00f6z\u00fcmlerine acilen ihtiya\u00e7 duyulan Hindistan ve Afrika pazarlar\u0131nda tan\u0131 eri\u015fimini aktif olarak geni\u015fletmektedir. Son D\u00fcnya Kanser G\u00fcn\u00fc etkinli\u011fi, Co-Diagnostics'in saf ticari \u00e7\u0131karlar\u0131n \u00f6tesinde kamu sa\u011fl\u0131\u011f\u0131 giri\u015fimlerine ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 vurgulam\u0131\u015ft\u0131r.<\/p> <p><strong>\u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: \u015eubat 2025'te Co-Diagnostics'in ortak giri\u015fimi CoSara Diagnostics, kaynaklar\u0131 s\u0131n\u0131rl\u0131 ortamlarda erken kanser tespitini devrimle\u015ftirebilecek uygun fiyatl\u0131 PCR teknolojisini g\u00f6sterdikleri benzersiz bir kanser fark\u0131ndal\u0131\u011f\u0131 etkinli\u011fi d\u00fczenledi - bilimsel yenili\u011fi k\u00fcresel sa\u011fl\u0131k savunuculu\u011fuyla harmanlayan nadir \u015firketlerden biri olarak.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p>26 A\u011fustos 2025 itibar\u0131yla, Co-Diagnostics, Inc. (CODX) hisseleri <strong>0,32 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor ve bu, ileri teknoloji molek\u00fcler tan\u0131 alan\u0131na maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in inan\u0131lmaz bir f\u0131rsat sunuyor. Bu fiyat seviyesi CODX&#8217;i kesinlikle kuru\u015f hisse senedi kategorisine yerle\u015ftiriyor, ancak bu sizi yan\u0131ltmas\u0131n &#8211; \u015firketin teknolojisi uygun fiyatl\u0131 PCR testlerini d\u00fcnya \u00e7ap\u0131nda devrim niteli\u011finde de\u011fi\u015ftirebilir.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: \u015eirketin bir sonraki kazan\u00e7 raporunu yay\u0131nlamas\u0131 beklenen <strong>Kas\u0131m 2025<\/strong> tarihini takviminize i\u015faretleyin. Tarihsel olarak, biyoteknoloji kazan\u00e7lar\u0131, duyurudan sonraki g\u00fcnlerde fiyatlarda %20-50 aras\u0131nda b\u00fcy\u00fck dalgalanmalara neden olabilir.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>Son performans desenlerine bakmak, Co-Diagnostics, Inc. (CODX) hissesine yat\u0131r\u0131m zamanlamas\u0131 i\u00e7in kritik i\u00e7g\u00f6r\u00fcler sa\u011flar:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<th>S\u00fcre<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>14 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>0,27 $<\/td>\n<td>%18,5 Art\u0131\u015f (1 hafta)<\/td>\n<td>S\u00fcrd\u00fcr\u00fclebilir<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>T\u00fcm Zamanlar\u0131n En D\u00fc\u015f\u00fc\u011f\u00fc<\/td>\n<td>0,23 $<\/td>\n<td>%39 Kurtarma<\/td>\n<td>3 ay<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>D\u00fcnya Kanser G\u00fcn\u00fc<\/td>\n<td>0,45 $<\/td>\n<td>%12 Momentum<\/td>\n<td>2 hafta<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>Platform Lansman\u0131<\/td>\n<td>0,82 $<\/td>\n<td>%28 D\u00fczeltme<\/td>\n<td>1 ay<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek 2024<\/td>\n<td>1,15 $<\/td>\n<td>%45 D\u00fc\u015f\u00fc\u015f<\/td>\n<td>6 ay<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Desen, olumlu klinik deneme g\u00fcncellemeleri veya d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131n\u0131n genellikle en s\u00fcrd\u00fcr\u00fclebilir kazan\u00e7lar\u0131 tetikledi\u011fini, kazan\u00e7 ka\u00e7\u0131rmalar\u0131n\u0131n ise keskin ancak genellikle ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden oldu\u011funu g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2>\n<p>Co-Diagnostics, 2025 y\u0131l\u0131n\u0131n ilk sekiz ay\u0131nda tam bir h\u0131z treni ya\u015fad\u0131 ve biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n neden g\u00fc\u00e7l\u00fc sinirler ve stratejik zamanlama gerektirdi\u011fini tam olarak g\u00f6sterdi:<\/p>\n<p><strong>Ocak-Mart 2025<\/strong>: \u015eirket, Logix Smart platformu i\u00e7in b\u00fcy\u00fck sa\u011fl\u0131k fuarlar\u0131na kat\u0131l\u0131rken hisse senedi 0,45-0,60 $ aras\u0131nda i\u015flem g\u00f6rd\u00fc ve piyasa fark\u0131ndal\u0131\u011f\u0131 olu\u015fturdu.<\/p>\n<p><strong>Nisan-May\u0131s 2025<\/strong>: Nakit yakma oranlar\u0131 ve gecikmi\u015f d\u00fczenleyici zaman \u00e7izelgeleri endi\u015feleri nedeniyle 22 May\u0131s&#8217;ta <strong>t\u00fcm zamanlar\u0131n en d\u00fc\u015f\u00fck seviyesi olan 0,2275 $<\/strong> seviyesine sert bir d\u00fc\u015f\u00fc\u015f ya\u015fand\u0131.<\/p>\n<p><strong>Haziran-A\u011fustos 2025<\/strong>: Beklenenden iyi gelen 2. \u00e7eyrek kazan\u00e7lar ve Co-Dx PCR platform geli\u015ftirmesindeki devam eden ilerlemeyle desteklenen <strong>%39&#8217;luk dikkate de\u011fer bir toparlanma<\/strong> ya\u015fand\u0131 ve fiyatlar yakla\u015f\u0131k 0,32 $ seviyesine y\u00fckseldi.<\/p>\n<p>Genel alt\u0131 ayl\u0131k performans, erken a\u015fama biyoteknoloji \u015firketlerine \u00f6zg\u00fc a\u015f\u0131r\u0131 volatilite ile <strong>V \u015feklinde bir toparlanma modeli<\/strong> g\u00f6steriyor. Hissenin beta katsay\u0131s\u0131 1,44 olup, piyasan\u0131n genelinden \u00e7ok daha fazla hareket etti\u011fini do\u011fruluyor ve sadece risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Co-Diagnostics&#8217;in \u00fcr\u00fcn hatt\u0131 ilerlemesi, piyasa konumu ve sekt\u00f6r trendlerinin kapsaml\u0131 analizine dayanarak, yat\u0131r\u0131mc\u0131lar\u0131n bekleyebilece\u011fi \u015funlard\u0131r:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: <strong>0,45-0,65 $<\/strong> &#8211; Platform geli\u015ftirmesinin devam\u0131 ve potansiyel d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 mevcut seviyelerden %40-100 aras\u0131 y\u00fckseli\u015f sa\u011flayabilir. \u2192 <strong>R\u0130SK TOLERANSI Y\u00dcKSEK YATIRIMCILAR \u0130\u00c7\u0130N SPEK\u00dcLAT\u0130F ALIM<\/strong><\/li>\n<li><strong>2026 Tahmini<\/strong>: <strong>0,80-1,20 $<\/strong> &#8211; Ba\u015far\u0131l\u0131 FDA ba\u015fvurular\u0131 ve ilk ticari lansmanlar i\u015f modelini do\u011frulayabilir ve kurumsal ilgiyi \u00e7ekebilir.<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: <strong>2,50-4,00 $<\/strong> &#8211; Birden fazla test paneli ve co\u011frafi pazarda tam ticarile\u015fme s\u00fcrd\u00fcr\u00fclebilir gelir ak\u0131\u015flar\u0131 olu\u015fturabilir.<\/li>\n<li><strong>2030 Vizyonu<\/strong>: <strong>5,00-8,00 $<\/strong> &#8211; Uygun fiyatl\u0131 PCR testlerinde pazar liderli\u011fi ve daha b\u00fcy\u00fck tan\u0131 \u015firketlerinden potansiyel sat\u0131n alma ilgisi.<\/li>\n<\/ul>\n<p><em>Karar<\/em>: CODX, y\u00fcr\u00fctme ba\u015far\u0131l\u0131 olursa 5 y\u0131l i\u00e7inde 15-25 kat getiri sa\u011flayabilecek y\u00fcksek riskli, potansiyel olarak y\u00fcksek getirili bir yat\u0131r\u0131md\u0131r, ancak d\u00fczenleyici veya finansman zorluklar\u0131 ortaya \u00e7\u0131karsa \u00f6nemli d\u00fc\u015f\u00fc\u015fler de ya\u015fayabilir.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<p>Co-Diagnostics, Inc. (CODX) hissesine yat\u0131r\u0131m yaparken bu kritik riskleri anlamak gerekir:<\/p>\n<h3>Y\u00fcksek Etkili Riskler<\/h3>\n<ul>\n<li><strong>D\u00fczenleyici Onay Gecikmeleri<\/strong>: \u015eirketin t\u00fcm de\u011feri, test panelleri i\u00e7in ba\u015far\u0131l\u0131 FDA 510(k) ba\u015fvurular\u0131na ba\u011fl\u0131d\u0131r. Herhangi bir gecikme veya reddedilme, hisse fiyat\u0131n\u0131 g\u00fcnler i\u00e7inde %50-70 oran\u0131nda d\u00fc\u015f\u00fcrebilir.<\/li>\n<li><strong>Nakit Yakma Krizi<\/strong>: 13,4 milyon $ rezerv ve \u00e7eyreklik yakla\u015f\u0131k 7,7 milyon $ zarar ile \u015firketin ek finansman gerektirmeden \u00f6nce yakla\u015f\u0131k 4-5 \u00e7eyreklik nakit \u00f6mr\u00fc vard\u0131r; bu finansman mevcut hissedarlar\u0131n hisselerini seyreltebilir.<\/li>\n<li><strong>M\u00fc\u015fteri Yo\u011funla\u015fmas\u0131<\/strong>: \u00dcr\u00fcn gelirinin %53&#8217;\u00fc \u00fc\u00e7 m\u00fc\u015fteriden gelmekte olup, herhangi bir b\u00fcy\u00fck m\u00fc\u015fterinin sipari\u015fleri azaltmas\u0131 veya tedarik\u00e7iyi de\u011fi\u015ftirmesi durumunda k\u0131r\u0131lganl\u0131k yaratmaktad\u0131r.<\/li>\n<\/ul>\n<h3>Piyasa Riskleri<\/h3>\n<ul>\n<li><strong>Biyoteknoloji Sekt\u00f6r\u00fc Volatilitesi<\/strong>: 2025&#8217;te sekt\u00f6r genel olarak yat\u0131r\u0131mc\u0131lar taraf\u0131ndan tercih edilmemekte, bu da sermaye eri\u015fimini azaltmakta ve geli\u015fim a\u015famas\u0131ndaki \u015firketler i\u00e7in bor\u00e7lanma maliyetlerini art\u0131rmaktad\u0131r.<\/li>\n<li><strong>Rekabetin Yo\u011funla\u015fmas\u0131<\/strong>: Daha b\u00fcy\u00fck ve daha derin ceplere sahip tan\u0131 \u015firketleri, Co-Diagnostics&#8217;in pazar avantaj\u0131n\u0131 zay\u0131flatabilecek uygun fiyatl\u0131 PCR platformlar\u0131 geli\u015ftirebilir.<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 Olumlu Sinyaller: Neden \u015eimdi Almay\u0131 D\u00fc\u015f\u00fcnmelisiniz?<\/h2>\n<p>Risklere ra\u011fmen, Co-Diagnostics, Inc. (CODX) hissesine yat\u0131r\u0131m yapmay\u0131 destekleyen birka\u00e7 g\u00fc\u00e7l\u00fc fakt\u00f6r vard\u0131r:<\/p>\n<ul>\n<li><strong>Teknoloji Farkl\u0131la\u015fmas\u0131<\/strong>: Patentli Co-Primers teknolojisi, PCR do\u011frulu\u011fu ve maliyet azalt\u0131m\u0131nda ger\u00e7ek bilimsel avantaj sa\u011flar ve hakemli ara\u015ft\u0131rmalarla do\u011frulanm\u0131\u015ft\u0131r.<\/li>\n<li><strong>Piyasa Zamanlamas\u0131<\/strong>: Uygun fiyatl\u0131 tan\u0131 testlerine k\u00fcresel talep artmaya devam ediyor, \u00f6zellikle Co-Diagnostics&#8217;in Hindistan ve Afrika&#8217;daki ortakl\u0131klar\u0131yla odakland\u0131\u011f\u0131 geli\u015fmekte olan pazarlarda.<\/li>\n<li><strong>Son Momentum<\/strong>: May\u0131s ay\u0131ndaki dipten %39&#8217;luk toparlanma, y\u00f6netimin y\u00fcr\u00fctme yeteneklerine ve zaman \u00e7izelgesine uyumuna y\u00f6nelik artan yat\u0131r\u0131mc\u0131 g\u00fcvenini g\u00f6steriyor.<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: Zorluklara ra\u011fmen analistler &#8220;Al&#8221; notlar\u0131n\u0131 koruyor ve ortalama fiyat hedefleri 5,50 $ ile %1600&#8217;den fazla potansiyel y\u00fckseli\u015fi temsil ediyor.<\/li>\n<li><strong>Sekt\u00f6r Etkinliklerine Kat\u0131l\u0131m<\/strong>: WHX Kuala Lumpur ve Next Generation Dx Summit&#8217;teki aktif kat\u0131l\u0131m, piyasa geli\u015ftirme ve ortakl\u0131k kurma taahh\u00fcd\u00fcn\u00fc g\u00f6steriyor.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan T\u00fcccarlar \u0130\u00e7in Stratejik Tavsiyeler<\/h2>\n<p>Co-Diagnostics, Inc. (CODX) hissesinin kapsaml\u0131 analizine dayanarak, bug\u00fcn hangi ad\u0131mlar\u0131n mant\u0131kl\u0131 oldu\u011fu a\u015fa\u011f\u0131da belirtilmi\u015ftir:<\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n Ama Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2&#8217;sinden fazlas\u0131n\u0131 CODX&#8217;e ay\u0131rmay\u0131n &#8211; ba\u015far\u0131l\u0131 olursa \u00f6nemli, ba\u015far\u0131s\u0131z olursa y\u0131k\u0131c\u0131 olmayacak kadar k\u00fc\u00e7\u00fck.<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede almak yerine, volatiliteyi dengelemek i\u00e7in her ay 100-200 $ de\u011ferinde hisse almay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li>\n<li><strong>A\u00e7\u0131k \u00c7\u0131k\u0131\u015f Kurallar\u0131 Belirleyin<\/strong>: Kar alaca\u011f\u0131n\u0131z (\u00f6rne\u011fin %100 kazan\u00e7) veya zarar kesme (\u00f6rne\u011fin %50 d\u00fc\u015f\u00fc\u015f) fiyatlar\u0131n\u0131 \u00f6nceden belirleyin, b\u00f6ylece duygusal kararlar almazs\u0131n\u0131z.<\/li>\n<li><strong>D\u00fczenleyici Tetikleyicileri \u0130zleyin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve FDA ba\u015fvuru duyurular\u0131 kritik olacak &#8211; bu olaylar i\u00e7in fiyat uyar\u0131lar\u0131 ayarlamay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li>\n<\/ol>\n<p><em>Esprili Deneyimli Yorum<\/em>: &#8220;CODX ticareti, kontroller olmadan PCR yapmak gibidir &#8211; bazen harika sonu\u00e7lar al\u0131rs\u0131n\u0131z, bazen kontaminasyon olur. Her zaman duygusal koruyucu ekipman tak\u0131n!&#8221;<\/p>\n<h2>\u2705 Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<p>Bu ilgin\u00e7 biyoteknoloji oyununu portf\u00f6y\u00fcn\u00fcze eklemeye haz\u0131r m\u0131s\u0131n\u0131z? \u0130\u015fte pratik yol haritan\u0131z:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu Se\u00e7in<\/td>\n<td>Makul komisyonlarla NASDAQ kuru\u015f hisse senedi ticareti sunan bir arac\u0131 kurum se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Y\u00fcksek riskli bu yat\u0131r\u0131m i\u00e7in k\u00fc\u00e7\u00fck bir miktar (100-500 $) ile ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;CODX&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Do\u011fru menkul k\u0131ymeti bulmak i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Hisse miktar\u0131 ve toplam maliyet dahil olmak \u00fczere emir detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td>\n<td>B\u00fcy\u00fck fiyat hareketleri veya haber olaylar\u0131 i\u00e7in bildirimleri yap\u0131land\u0131r\u0131n<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Tezinizi Belgeleyin<\/td>\n<td>Neden yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131z\u0131 ve ne zaman sataca\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u00c7eyreklik \u0130zleyin<\/td>\n<td>Kazan\u00e7 raporlar\u0131 ve klinik deneme g\u00fcncellemelerini d\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td>\n<td>Bekleme s\u00fcresinin sermaye kazanc\u0131 muamelesini nas\u0131l etkiledi\u011fini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Bilgili Kal\u0131n<\/td>\n<td>\u015eirket bas\u0131n b\u00fcltenlerini ve sekt\u00f6r geli\u015fmelerini takip edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option&#8217;\u0131n CODX Yat\u0131r\u0131mc\u0131lar\u0131na \u00c7ekicili\u011fi<\/h2>\n<p>Co-Diagnostics gibi \u015firketlerle ilgilenen t\u00fcccarlar i\u00e7in Pocket Option, biyoteknoloji yat\u0131r\u0131m stratejileriyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, CODX yat\u0131r\u0131m tezini minimal sermaye riskiyle test edebilir ve biyoteknoloji ticaretinin inceliklerini \u00f6\u011frenebilirsiniz.<\/li>\n<li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci sayesinde, hesap onay\u0131 i\u00e7in g\u00fcnler beklemeden ani fiyat hareketlerinden veya son dakika haberlerinden yararlanabilirsiniz.<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100&#8217;den fazla para \u00e7ekme y\u00f6ntemi, CODX&#8217;in ba\u015far\u0131l\u0131 biyoteknoloji hisselerine \u00f6zg\u00fc patlay\u0131c\u0131 yukar\u0131 hareketlerinde karlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim sa\u011flar.<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, CODX gibi volatil hisseleri ger\u00e7ek zamanl\u0131 grafikler ve haber entegrasyonu ile izlemeyi kolayla\u015ft\u0131r\u0131r ve kritik FDA duyuru pencerelerinde bilin\u00e7li kararlar vermenize yard\u0131mc\u0131 olur.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Co-Diagnostics: Tan\u0131 Devrimine Haz\u0131rl\u0131k<\/h2>\n<p>Co-Diagnostics, t\u0131bbi teknoloji ile k\u00fcresel sa\u011fl\u0131k eri\u015filebilirli\u011finin b\u00fcy\u00fcleyici kesi\u015fim noktas\u0131nda faaliyet g\u00f6stermektedir. \u015eirketin temel misyonu, yenilik\u00e7i Co-Dx platformu arac\u0131l\u0131\u011f\u0131yla alt\u0131n standart PCR testlerini demokratikle\u015ftirmek ve laboratuvar kalitesinde tan\u0131 hizmetlerini \u00f6nemli \u00f6l\u00e7\u00fcde azalt\u0131lm\u0131\u015f maliyetlerle sunmakt\u0131r.<\/p>\n<p>\u015eu anda gelir \u00f6ncesi bir yenilik\u00e7i olarak konumlanan Co-Diagnostics, COVID-19, t\u00fcberk\u00fcloz, solunum \u00e7oklu test ve HPV \u00e7oklu test olmak \u00fczere d\u00f6rt geli\u015fmi\u015f test paneli geli\u015ftirmektedir. \u015eirketin WHX Kuala Lumpur ve Next Generation Dx Summit gibi b\u00fcy\u00fck sekt\u00f6r etkinliklerine kat\u0131l\u0131m\u0131, ortakl\u0131klar kurma ve piyasa fark\u0131ndal\u0131\u011f\u0131 olu\u015fturma taahh\u00fcd\u00fcn\u00fc g\u00f6stermektedir.<\/p>\n<p>Ortak giri\u015fimi CoSara Diagnostics arac\u0131l\u0131\u011f\u0131yla \u015firket, \u00f6zellikle uygun fiyatl\u0131 test \u00e7\u00f6z\u00fcmlerine acilen ihtiya\u00e7 duyulan Hindistan ve Afrika pazarlar\u0131nda tan\u0131 eri\u015fimini aktif olarak geni\u015fletmektedir. Son D\u00fcnya Kanser G\u00fcn\u00fc etkinli\u011fi, Co-Diagnostics&#8217;in saf ticari \u00e7\u0131karlar\u0131n \u00f6tesinde kamu sa\u011fl\u0131\u011f\u0131 giri\u015fimlerine ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 vurgulam\u0131\u015ft\u0131r.<\/p>\n<p><strong>\u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: \u015eubat 2025&#8217;te Co-Diagnostics&#8217;in ortak giri\u015fimi CoSara Diagnostics, kaynaklar\u0131 s\u0131n\u0131rl\u0131 ortamlarda erken kanser tespitini devrimle\u015ftirebilecek uygun fiyatl\u0131 PCR teknolojisini g\u00f6sterdikleri benzersiz bir kanser fark\u0131ndal\u0131\u011f\u0131 etkinli\u011fi d\u00fczenledi &#8211; bilimsel yenili\u011fi k\u00fcresel sa\u011fl\u0131k savunuculu\u011fuyla harmanlayan nadir \u015firketlerden biri olarak.<\/p>\n"},"faq":[{"question":"Co-Diagnostics (CODX) hisseleri nereden al\u0131nabilir?","answer":"CODX hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"CODX hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda d\u00fczenleyici onay gecikmeleri, nakit yakma krizi ve m\u00fc\u015fteri gelirlerinin yo\u011funla\u015fmas\u0131 yer almaktad\u0131r. Ayr\u0131ca biyoteknoloji sekt\u00f6r\u00fcndeki y\u00fcksek volatilite de risk fakt\u00f6r\u00fcd\u00fcr."},{"question":"CODX hisseleri i\u00e7in 2025 y\u0131l sonu fiyat hedefi nedir?","answer":"Analizlere g\u00f6re 2025 y\u0131l sonu fiyat hedefi 0,45-0,65 $ aral\u0131\u011f\u0131ndad\u0131r ve bu, mevcut seviyelerden %40-100 aras\u0131nda bir y\u00fckseli\u015f potansiyeli sunmaktad\u0131r."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, net \u00e7\u0131k\u0131\u015f stratejileri belirleyin ve d\u00fczenleyici geli\u015fmeleri yak\u0131ndan takip edin."},{"question":"Pocket Option platformu CODX yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunmas\u0131 nedeniyle CODX gibi volatil biyoteknoloji hisseleri i\u00e7in ideal bir platformdur."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Co-Diagnostics (CODX) hisseleri nereden al\u0131nabilir?","answer":"CODX hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"CODX hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda d\u00fczenleyici onay gecikmeleri, nakit yakma krizi ve m\u00fc\u015fteri gelirlerinin yo\u011funla\u015fmas\u0131 yer almaktad\u0131r. Ayr\u0131ca biyoteknoloji sekt\u00f6r\u00fcndeki y\u00fcksek volatilite de risk fakt\u00f6r\u00fcd\u00fcr."},{"question":"CODX hisseleri i\u00e7in 2025 y\u0131l sonu fiyat hedefi nedir?","answer":"Analizlere g\u00f6re 2025 y\u0131l sonu fiyat hedefi 0,45-0,65 $ aral\u0131\u011f\u0131ndad\u0131r ve bu, mevcut seviyelerden %40-100 aras\u0131nda bir y\u00fckseli\u015f potansiyeli sunmaktad\u0131r."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, net \u00e7\u0131k\u0131\u015f stratejileri belirleyin ve d\u00fczenleyici geli\u015fmeleri yak\u0131ndan takip edin."},{"question":"Pocket Option platformu CODX yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunmas\u0131 nedeniyle CODX gibi volatil biyoteknoloji hisseleri i\u00e7in ideal bir platformdur."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T07:26:00+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-26T07:26:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/\",\"name\":\"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-26T07:26:00+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/","og_locale":"tr_TR","og_type":"article","og_title":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-26T07:26:00+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-26T07:26:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/","name":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-26T07:26:00+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-diagnostics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Co-Diagnostics, Inc. (CODX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Co-Diagnostics, Inc. (CODX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":352230,"slug":"how-to-buy-diagnostics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Co-Diagnostics, Inc. (CODX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Co-Diagnostics, Inc. (CODX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-diagnostics\/"},"pt_AA":{"locale":"pt_AA","id":352237,"slug":"how-to-buy-diagnostics","post_title":"Como comprar a\u00e7\u00f5es da Co-Diagnostics, Inc. (CODX) - Investimento em a\u00e7\u00f5es da Co-Diagnostics, Inc. (CODX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-diagnostics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=352231"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352231\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=352231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=352231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=352231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}